Navigation Links
Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/25/2011

NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0661232/Osteoporosis-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global osteoporosis therapeutics market. The report identifies the key trends shaping and driving the global osteoporosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoporosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData analysis shows that the global osteoporosis therapeutics market stood at $6.9 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $8.5 billion in 2010. GlobalData forecasts that the global osteoporosis therapeutics market will grow moderately at a CAGR of 3.3% over the next eight years to reach $11.1 billion by 2018. The current competitive landscape consists mainly of bisphosphonates, selective estrogen receptor modulators (SERM), receptor activator of nuclear factor kappa-B (RANK) ligand (RANKL) inhibitor drugs and hormone therapy, which includes parathyroid hormone apart from estrogen and progesterone. The recent launch of Prolia (denosumab), a monoclonal antibody from the therapeutic class RANKL inhibitor, has also opened new avenues for the treatment of osteoporosis with improved safety, efficacy and compliance to medication by the patient. The bisphosphonates are the preferred drug for treatment and are used as the first line of therapy for the treatment of osteoporosis. The expected moderate growth can be attributed to the increase in awareness among people regarding osteoporosis, especially among females about postmenopausal osteoporosis (PMO) which contributes the largest number of patient pool to osteoporosis. GlobalData also predicts that an increase in the patient population as a consequence of the ageing population will drive the moderate growth in the osteoporosis therapeutics market. The modest growth observed in the osteoporosis therapeutics market during 2010 to 2018 can also be attributed to the expected launch of pipeline products such as Odanacatib (MK 0822), NB S101 during the late forecast period. The patent expiry of Actonel (risedronate sodium), Boniva (ibandronate), Reclast (zoledronic acid), Evista (raloxifene) and Protelos (strontium malonate) during 2012 to 2014 will act as the major barriers for the growth of osteoporosis therapeutics market during the forecast period. The impending patent expiry of Boniva in 2012; Actonel and Reclast in 2013; and Evista in 2014 means patients will have access to treatment at much lower prices reflecting brand erosion of these drugs. The sales growth will also be affected by Fosamax (alendronate) generics, which lost its patent exclusivity in 2008. The main treatment options available in the osteoporosis therapeutics market include alendronate, Reclast, Actonel, Boniva, Evista, Prolia, Forteo (teriparatide), Miacalcin (calcitonin salmon), Prempro (estrogen) and Premarin (conjugated estrogens and medroxyprogesterone acetate) among others.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the osteoporosis therapeutics market. Its scope includes -

- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) osteoporosis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as osteoclast activity inhibitors, osteoclast activity promoters, bone anabolic agents, SERMs, SARMs, RANKL inhibitors, dual acting bone agents, PTH release stimulator, cathepsin K inhibitor, bone morphogenetic protein signaler, aminobisphosphonate, DKK1 Protein inhibitor and osteoblast level promotor

- Analysis of the current and future competition in the seven key countries osteoporosis therapeutics market. Key market players covered are Amgen, Merck, Novartis, Pfizer, Osteologix, EffRx, Zydus, Astellas and Radius.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoporosis therapeutics therapeutics market.

- Analysis of key recent licensing and partnership agreements in osteoporosis therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global osteoporosis therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoporosis therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global osteoporosis therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 7

2 Osteoporosis Therapeutics: Executive Summary 9

2.1 The Osteoporosis Therapeutics Market Forecast to Show Moderate Growth Through 2018 Due to Genericization of Branded Drugs 9

2.2 Availability of Different Treatment Options in the Current Osteoporosis Therapeutics Market, Catering Inadequately to the Needs of Patients 10

2.3 Strong Pipeline Products Likely to Enter the Market, Uncovering Better Treatment Options 11

2.4 Significant Unmet Need in Osteoporosis Therapeutics Market Accounted by Low Levels of Drug Safety and Compliance to Medication 12

3 Osteoporosis Therapeutics: Introduction 14

3.1 Disease Overview 14

3.2 Epidemiology 17

3.3 Etiology 18

3.4 Pathophysiology 19

3.5 Signs and Symptoms 21

3.6 Diagnosis 22

3.6.1 Physical Examination 22

3.6.2 Medical History 23

3.6.3 BMD Testing 23

3.6.4 Laboratory Tests 25

3.7 Treatment and Management Options 25

3.8 GlobalData Pipeline Report Guidance 29

4 Osteoporosis Therapeutics: Market Characterization 31

4.1 Osteoporosis Therapeutics Market Size (2005–2010) – Global 31

4.2 Osteoporosis Therapeutics Market Forecast (2010–2018) – Global 32

4.3 Osteoporosis Therapeutics Market Size (2005–2010) – The US 34

4.4 Osteoporosis Therapeutics Market Forecast (2010–2018) – The US 35

4.5 Osteoporosis Therapeutics Market Size (2005–2010) – France 37

4.6 Osteoporosis Therapeutics Market Forecast (2010–2018) – France 38

4.7 Osteoporosis Therapeutics Market Size (2005–2010) – Germany 39

4.8 Osteoporosis Therapeutics Market Forecast (2010–2018) – Germany 40

4.9 Osteoporosis Therapeutics Market Size (2005–2010) – Italy 41

4.10 Osteoporosis Therapeutics Market Forecast (2010–2018) – Italy 42

4.11 Osteoporosis Therapeutics Market Size (2005–2010) – Spain 44

4.12 Osteoporosis Therapeutics Market Forecast (2010–2018) – Spain 45

4.13 Osteoporosis Therapeutics Market Size (2005–2010) – The UK 46

4.14 Osteoporosis Therapeutics Market Forecast (2010–2018) – The UK 47

4.15 Osteoporosis Therapeutics Market Size (2005–2010) – Japan 49

4.16 Osteoporosis Therapeutics Market Forecast (2010–2018) – Japan 50

4.17 Drivers and Barriers for the Osteoporosis Therapeutics Market 51

4.17.1 Drivers for the Osteoporosis Therapeutics Market 51

4.17.2 Barriers for the Postmenopausal Osteoporosis Therapeutics Market 52

4.18 Opportunity and Unmet Need 54

4.19 Key Takeaway 57

5 Osteoporosis Therapeutics: Competitive Assessment 58

5.1 Overview 58

5.2 Strategic Competitor Assessment 58

5.3 Product Profile for the Major Marketed Products in the Osteoporosis Therapeutics Market 60

5.3.1 Fosamax (alendronate sodium) 60

5.3.2 Actonel (risedronate sodium) 62

5.3.3 Boniva (ibandronate sodium) 64

5.3.4 Reclast (zoledronic acid) 66

5.3.5 Evista (raloxifene hydrochloride) 68

5.3.6 Prolia (denosumab) 70

5.3.7 Forteo (teriparatide [rDNA origin]) injection 71

5.3.8 Miacalcin (salmon calcitonin) 74

5.3.9 Activella (estradiol, norethindrone acetate) 75

5.3.10 Premarin (estrogen) 76

5.3.11 Prempro (conjugated estrogens and medroxyprogesterone acetate) 77

5.4 Key Takeaway 78

6 Osteoporosis Therapeutics: Pipeline Assessment 79

6.1 Overview 79

6.2 Strategic Pipeline Assessment 79

6.3 Osteoporosis Therapeutics – Pipeline Analysis by Clinical Phase of Development 79

6.3.1 Osteoporosis Therapeutics – Phase III and Regulatory Filed Clinical Pipeline 80

6.3.2 Osteoporosis Therapeutics – Phase II Clinical Pipeline 81

6.3.3 Osteoporosis Therapeutics – Phase I Pipeline 82

6.3.4 Osteoporosis Therapeutics –Pre-clinical and Discovery Phase Pipeline 83

6.4 Osteoporosis Therapeutics – Pipeline by Mechanism of Action 84

6.5 Technology Trends Analytical Framework 85

6.6 Osteoporosis Therapeutics – Most Promising Drugs in Clinical Development 87

6.7 Most Promising Drugs in Clinical Development 88

6.7.1 Viviant 88

6.7.2 Fablyn 89

6.7.3 Aprela 90

6.7.4 EX101 91

6.7.5 Odanacatib (MK-0822) 92

6.7.6 NB S101 93

6.7.7 SMC 021 94

6.7.8 Ostora 94

6.7.9 BA058- injection 96

6.7.10 UNI-PH (1-34), rhPTH 1-34 96

6.7.11 YM529 / ONO-5920 --- Astellas/ ONO 97

6.8 Key Takeaway 97

7 Osteoporosis Therapeutics: Clinical Trials Mapping 98

7.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 98

7.2 Clinical Trials by Phase of Clinical Development 99

7.3 Clinical Trials by Trial Status 100

7.4 Prominent Sponsors 101

7.5 Clinical Trials by Sponsors 102

7.6 Top Companies Participating in Osteoporosis Therapeutics Clinical Trials 103

8 Osteoporosis Therapeutics: Strategic Assessment 105

8.1 Key Events Impacting the Future Market 105

8.2 Future Market Competition Scenario 105

9 Osteoporosis Therapeutics: Future Players 108

9.1 Introduction 108

9.2 Company Profiles 108

9.2.1 Amgen Inc. 108

9.2.2 Astellas Pharma, Inc. 111

9.2.3 EffRx, Inc. 113

9.2.4 Merck & Co., Inc. 114

9.2.5 Novartis AG 115

9.2.6 Osteologix, Inc. 117

9.2.7 Pfizer Inc. 118

9.2.8 Radius Health, Inc 122

9.2.9 Tarsa Inc. 123

9.2.10 Zyduscadila Inc. 123

9.3 Other Companies in the Osteoporosis Therapeutics Market 126

9.4 Key Takeaway 129

10 Osteoporosis Therapeutics: Licensing & Partnership Deals 129

11 Osteoporosis Therapeutics: Appendix 140

11.1 Market Definitions 140

11.2 Abbreviations 140

11.3 Research Methodology 142

11.3.1 Coverage 142

11.3.2 Secondary Research 142

11.3.3 Forecasting 143

11.3.4 Primary Research 145

11.3.5 Expert Panel Validation 146

11.4 Contact Us 146

11.5 Disclaimer 146

11.6 Bibliography 147

List of Tables

Table 1: Difference Between Type I and Type II Osteoporosis 19

Table 2: Osteoporosis Prevalence and Low Bone Mass in People Aged 50 and Over (The US) (million)* 21

Table 3: Difference Between Diagnostic Techniques Used for BMD Measurement 27

Table 4: WHO Classification for Diagnosis of Osteoporosis Using BMD Measurements 27

Table 5: Approved Drugs for the Prevention and Treatment of Postmenopausal Osteoporosis 31

Table 6: Dosage Schedule for Drugs Used for the Treatment of Osteoporosis 31

Table 7: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2005–2010 35

Table 8: Osteoporosis Therapeutics Market, Global, Forecast ($bn), 2010–2018 37

Table 9: Osteoporosis Therapeutics Market, The US, Revenue ($bn), 2005–2010 38

Table 10: Osteoporosis Therapeutics Market, The US, Forecast ($bn), 2010–2018 39

Table 11: Osteoporosis Therapeutics Market, France, Revenue ($bn), 2005–2010 41

Table 12: Osteoporosis Therapeutics Market, France, Forecast ($bn), 2010–2018 42

Table 13: Osteoporosis Therapeutics Market, Germany, Revenue ($bn), 2005–2010 43

Table 14: Osteoporosis Therapeutics Market, Germany, Forecast ($bn), 2010–2018 44

Table 15: Osteoporosis Therapeutics Market, Italy, Revenue ($bn), 2005–2010 45

Table 16: Osteoporosis Therapeutics Market, Italy, Forecast ($bn), 2010–2018 46

Table 17: Osteoporosis Therapeutics Market, Spain, Revenue ($bn), 2005–2010 48

Table 18: Osteoporosis Therapeutics Market, Spain, Forecast ($bn), 2010–2018 49

Table 19: Osteoporosis Therapeutics Market, The UK, Revenue ($bn), 2005–2010 50

Table 20: Osteoporosis Therapeutics Market, The UK, Forecast ($bn), 2010–2018 51

Table 21: Osteoporosis Therapeutics Market, Japan, Revenue ($bn), 2005–2010 53

Table 22: Osteoporosis Therapeutics Market, Japan, Forecast ($bn), 2010–2018 54

Table 23: Effect of Actonel on the Risk of Vertebral Fractures 67

Table 24: Effect of Evista on Risk of Vertebral Fractures 72

Table 25: Effect of Evista on Increases in BMD vs. Placebo 73

Table 26: Effect of Forteo on Risk of Vertebral Fractures in Postmenopausal Women with Osteoporosis 76

Table 27: Mean Percentage Change in BMD in Postmenopausal Women with Osteoporosis 76

Table 28: Osteoporosis Therapeutics Market, Phase III and Regulatory Filed Pipeline, 2011 84

Table 29: Osteoporosis Therapeutics Market, Phase II Pipeline, 2011 85

Table 30: Osteoporosis Therapeutics Market, Phase I Pipeline, 2011 86

Table 31: Osteoporosis Therapeutics Market, Pre-clinical and Discovery Phase Pipeline, 2011 87

Table 32: Osteoporosis Therapeutics Market, Global, Most Promising Drugs in Clinical Development, 2011 90

Table 33: Osteoporosis Therapeutics, Global, Clinical Trials, 2011 102

Table 34: Osteoporosis Therapeutics, Global, Clinical Trials by Phase, 2011 103

Table 35: Osteoporosis Therapeutics, Global, Clinical Trials by Status of Development, 2011 104

Table 36: Osteoporosis Therapeutics, Global, Prominent Sponsors, 2011 105

Table 37: Osteoporosis Therapeutics, Global, Overall Sponsors, 2011 106

Table 38: Osteoporosis Therapeutics, Global, Top Ten Companies by Phase, 2011 107

Table 39: Amgen Inc.– Osteoporosis Pipeline, 2011 114

Table 40: Astellas Pharma, Inc. – Osteoporosis Pipeline, 2011 116

Table 41: EffRx, Inc. – Osteoporosis Pipeline, 2011 117

Table 42: Merck & Co., Inc.– Osteoporosis Pipeline, 2011 118

Table 43: Novartis AG – Osteoporosis Pipeline, 2011 120

Table 44: Osteologix,Inc. – Osteoporosis Pipeline, 2011 121

Table 45: Pfizer Inc. .– Osteoporosis Pipeline, 2011 125

Table 46: Radius Health Inc. – Osteoporosis Pipeline, 2011 126

Table 47: Tarsa Inc. – Osteoporosis Pipeline, 2011 126

Table 48: ZydusCadila Inc. – Osteoporosis Pipeline, 2011 129

Table 49: Osteoporosis Therapeutics Market – Future Players 129

Table 50: Osteoporosis Therapeutics, Global, Deals – 2011 133

List of Figures

Figure 1: Osteoporosis Therapeutics Market, Global, Revenue ($m), 2005–2018 13

Figure 2: Opportunity and Unmet Need in the Osteoporosis Therapeutics Market 16

Figure 3: Micro-architechture of Osteoporotic and Normal Bone 18

Figure 4: Classification of Osteoporosis 18

Figure 5: Image Depicting Osteoporotic Bone Condition 23

Figure 6: Common Fracture Sites 24

Figure 7: Treatment Algorithm for Osteoporosis 29

Figure 8: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2005–2010 35

Figure 9: Osteoporosis Therapeutics Market, Global, Forecast ($bn), 2010–2018 37

Figure 10: Osteoporosis Therapeutics Market, The US, Revenue ($bn), 2005–2010 38

Figure 11: Osteoporosis Therapeutics Market, The US, Forecast ($bn), 2010–2018 39

Figure 12: Osteoporosis Therapeutics Market, France, Revenue ($bn), 2005–2010 40

Figure 13: Osteoporosis Therapeutics Market, France, Forecast ($bn), 2010–2018 41

Figure 14: Osteoporosis Therapeutics Market, Germany, Revenue ($bn), 2005–2010 43

Figure 15: Osteoporosis Therapeutics Market, Germany, Forecast ($bn), 2010–2018 44

Figure 16: Osteoporosis Therapeutics Market, Italy, Revenue ($bn), 2005–2010 45

Figure 17: Osteoporosis Therapeutics Market, Italy, Forecast ($bn), 2010–2018 46

Figure 18: Osteoporosis Therapeutics Market, Spain, Revenue ($bn), 2005–2010 47

Figure 19: Osteoporosis Therapeutics Market, Spain, Forecast ($bn), 2010–2018 48

Figure 20: Osteoporosis Therapeutics Market, The UK, Revenue ($bn), 2005–2010 49

Figure 21: Osteoporosis Therapeutics Market, The UK, Forecast ($bn), 2010–2018 51

Figure 22: Osteoporosis Therapeutics Market, Japan, Revenue ($bn), 2005–2010 52

Figure 23: Osteoporosis Therapeutics Market, Japan, Forecast ($bn), 2010–2018 53

Figure 24: Opportunity and Unmet Need in the Osteoporosis Therapeutics Market 59

Figure 25: Strategic Competitor Assessment of the Marketed Products in Osteoporosis Therapeutics, 2011 63

Figure 26: Osteoporosis Therapeutics Pipeline by Phase of Clinical Development, 2011 83

Figure 27: Osteoporosis Therapeutics Market, Global, Pipeline by Mechanism of Action (%), 2011 88

Figure 28: Technology Trends Analytics Framework, 2011 89

Figure 29: Technology Trends Analytics Frame Work – Description, 2011 89

Figure 30: Osteoporosis Therapeutics, Global, Clinical Trials by Country, 2011 101

Figure 31: Osteoporosis Therapeutics, Global, Clinical Trials by Phase (%), 2011 102

Figure 32: Osteoporosis Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 103

Figure 33: Osteoporosis Therapeutics, Global, Prominent Sponsors (%), 2011 104

Figure 34: Osteoporosis Therapeutics, Global, Overall Sponsors (%), 2011 106

Figure 35: Osteoporosis Therapeutics, Global, Top Ten Companies by Phase, 2011 107

Figure 36: Osteoporosis Therapeutics Market, Drivers and Restraints, 2011 108

Figure 37: Implications for Future Market Competition in the Osteoporosis Therapeutics Market, 2011 109

Figure 38: Osteoporosis Therapeutics Market, Global, Future Players, 2011 111

Figure 39: GlobalData Market Forecasting Model 148Amgen Inc.

Astellas Pharma, Inc.

EffRx, Inc.

Merck & Co., Inc.

Novartis AG

Osteologix, Inc.

Pfizer Inc.

Radius Health, Inc

Tarsa Inc.

Zyduscadila Inc.

To order this report:

Pathology Industry: Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis
2. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
3. Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
4. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
5. Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis
6. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
7. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
8. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
9. Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease
10. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
11. $1,700,000 Funding of NeoStems Very Small Embryonic-Like Stem Cells Being Developed to Treat Osteoporosis Recommended by the Department of Defense Peer Reviewed Medical Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
Breaking Medicine News(10 mins):